IL-6 和骨保护素在 Graves 病患者骨代谢中的作用。

The role of IL-6 and osteoprotegerin in bone metabolism in patients with Graves' disease.

机构信息

Department of Endocrinology and Metabolism, Ankara Training and Research Hospital, University of Health Sciences, Ankara, Turkey.

Department of Clinical Biochemistry, Ankara Numune Training and Research Hospital, University of Health Sciences, Ankara, Turkey.

出版信息

Turk J Med Sci. 2022 Apr;52(2):338-345. doi: 10.55730/1300-0144.5320. Epub 2022 Apr 14.

DOI:10.55730/1300-0144.5320

PMID:36161625

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10381196/

Abstract

BACKGROUND

Increased bone turnover is a hallmark of hyperthyroidism. The underlying factors of how thyroid hormones affect bone cells are still under the spotlight. Previous studies indicated serum osteoprotegerin (OPG), receptor activator of NF-kB ligand (RANKL), and interleukin-6 (IL-6) as mediators of the effect of thyroid hormones on bone metabolism. Ultimately, the present research aimed to examine the association of IL-6 with OPG and RANKL in patients with hyperthyroidism.

METHODS

We carried out this study with 39 newly diagnosed and untreated Graves' patients and 43 healthy controls. In addition to routine tests, we measured serum OPG, RANKL, and IL-6 levels.

RESULTS

Mean age and sex distribution were similar in both groups. The hyperthyroid group had significantly higher OPG (p = 0.002) and IL-6 (p < 0.001) levels, but RANKL levels were significantly lower in this group (p < 0.001). We found OPG not to correlate with free T4 and T3, while it had a moderate and negative correlation with thyrotropin (TSH) (r = -0.372, p = 0.001). IL-6 had no correlation with OPG but positively correlated with free T4 (r = 0.445, p < 0.001) and free T3 (r = 0.326, p = 0.035). It also negatively correlated with RANKL (r = -0.247, p = 0.033).

DISCUSSION

Maintaining skeletal development and integrity is partially regulated by a normal balance of thyroid hormones. We concluded that increases in serum OPG and IL-6 levels accompanied hyperthyroidism. However, excessive levels of the hormones might cause drops in serum RANKL levels. Our results suggested that OPG, RANKL, and IL-6 might be involved in the cross-talking among immunity, thyroid function, and bone metabolism in the case of hyperthyroidism.

摘要

背景

骨转换增加是甲状腺功能亢进的标志。甲状腺激素影响骨细胞的潜在因素仍备受关注。先前的研究表明，血清骨保护素（OPG）、核因子-κB 配体（RANKL）和白细胞介素-6（IL-6）是甲状腺激素对骨代谢影响的介质。最终，本研究旨在检查甲状腺功能亢进患者中 IL-6 与 OPG 和 RANKL 的相关性。

方法

我们对 39 名新诊断和未经治疗的格雷夫斯病患者和 43 名健康对照者进行了这项研究。除了常规检查外，我们还测量了血清 OPG、RANKL 和 IL-6 水平。

结果

两组的平均年龄和性别分布相似。甲状腺功能亢进组的 OPG（p=0.002）和 IL-6（p<0.001）水平显著升高，而 RANKL 水平显著降低（p<0.001）。我们发现 OPG 与游离 T4 和游离 T3 不相关，而与促甲状腺激素（TSH）呈中度负相关（r=-0.372，p=0.001）。IL-6 与 OPG 无相关性，但与游离 T4 呈正相关（r=0.445，p<0.001）和游离 T3 呈正相关（r=0.326，p=0.035）。它还与 RANKL 呈负相关（r=-0.247，p=0.033）。